163 related articles for article (PubMed ID: 26751406)
1. Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and Egyptians.
Hamadeh IS; Shahin MH; Lima SM; Oliveira F; Wilson L; Khalifa SI; Langaee TY; Cooper-DeHoff RM; Cavallari LH; Johnson JA
Clin Transl Sci; 2016 Feb; 9(1):36-42. PubMed ID: 26751406
[TBL] [Abstract][Full Text] [Related]
2. Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans.
Cavallari LH; Perera M; Wadelius M; Deloukas P; Taube G; Patel SR; Aquino-Michaels K; Viana MA; Shapiro NL; Nutescu EA
Pharmacogenet Genomics; 2012 Feb; 22(2):152-8. PubMed ID: 22158446
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.
Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Balachander J; Sai Chandran BV; Adithan C
Eur J Clin Pharmacol; 2014 Jan; 70(1):47-56. PubMed ID: 24019055
[TBL] [Abstract][Full Text] [Related]
4. Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms.
Wypasek E; Branicka A; Awsiuk M; Sadowski J; Undas A
Thromb Res; 2014 Sep; 134(3):604-9. PubMed ID: 25042728
[TBL] [Abstract][Full Text] [Related]
5. Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose.
Rieder MJ; Reiner AP; Rettie AE
J Thromb Haemost; 2007 Nov; 5(11):2227-34. PubMed ID: 17764537
[TBL] [Abstract][Full Text] [Related]
6. Genetic determinants of variability in warfarin response after the dose-titration phase.
Iwuchukwu OF; Ramirez AH; Shi Y; Bowton EA; Kawai VK; Schildcrout JS; Roden DM; Denny JC; Stein CM
Pharmacogenet Genomics; 2016 Nov; 26(11):510-516. PubMed ID: 27632229
[TBL] [Abstract][Full Text] [Related]
7. New genetic variant that might improve warfarin dose prediction in African Americans.
Schelleman H; Brensinger CM; Chen J; Finkelman BS; Rieder MJ; Kimmel SE
Br J Clin Pharmacol; 2010 Sep; 70(3):393-9. PubMed ID: 20716240
[TBL] [Abstract][Full Text] [Related]
8. The association between GGCX, miR-133 genetic polymorphisms and warfarin stable dosage in Han Chinese patients with mechanical heart valve replacement.
Tang XY; Zhang J; Peng J; Tan SL; Zhang W; Song GB; Liu LM; Li CL; Ren H; Zeng L; Liu ZQ; Chen XP; Zhou XM; Zhou HH; Hu JX; Li Z
J Clin Pharm Ther; 2017 Aug; 42(4):438-445. PubMed ID: 28429387
[TBL] [Abstract][Full Text] [Related]
9. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.
Limdi NA; Beasley TM; Crowley MR; Goldstein JA; Rieder MJ; Flockhart DA; Arnett DK; Acton RT; Liu N
Pharmacogenomics; 2008 Oct; 9(10):1445-58. PubMed ID: 18855533
[TBL] [Abstract][Full Text] [Related]
10. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
[TBL] [Abstract][Full Text] [Related]
11. Impact of
Li W; Zhao P; Chen L; Lai X; Shi G; Li L; Dong J
Pharmacogenomics; 2020 Jan; 21(2):101-110. PubMed ID: 31854268
[No Abstract] [Full Text] [Related]
12. Common VKORC1 and GGCX polymorphisms associated with warfarin dose.
Wadelius M; Chen LY; Downes K; Ghori J; Hunt S; Eriksson N; Wallerman O; Melhus H; Wadelius C; Bentley D; Deloukas P
Pharmacogenomics J; 2005; 5(4):262-70. PubMed ID: 15883587
[TBL] [Abstract][Full Text] [Related]
13. Implications of Polymorphisms in the BCKDK and GATA-4 Gene Regions on Stable Warfarin Dose in African Americans.
Bargal SA; Kight JN; Augusto de Oliveira F; Shahin MH; Langaee T; Gong Y; Hamadeh IS; Cooper-DeHoff RM; Cavallari LH
Clin Transl Sci; 2021 Mar; 14(2):492-496. PubMed ID: 33278335
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.
Limdi NA; Arnett DK; Goldstein JA; Beasley TM; McGwin G; Adler BK; Acton RT
Pharmacogenomics; 2008 May; 9(5):511-26. PubMed ID: 18466099
[TBL] [Abstract][Full Text] [Related]
15. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.
Limdi NA; Wadelius M; Cavallari L; Eriksson N; Crawford DC; Lee MT; Chen CH; Motsinger-Reif A; Sagreiya H; Liu N; Wu AH; Gage BF; Jorgensen A; Pirmohamed M; Shin JG; Suarez-Kurtz G; Kimmel SE; Johnson JA; Klein TE; Wagner MJ;
Blood; 2010 May; 115(18):3827-34. PubMed ID: 20203262
[TBL] [Abstract][Full Text] [Related]
16. Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy.
Khalighi K; Cheng G; Mirabbasi S; Khalighi B; Wu Y; Fan W
J Thromb Thrombolysis; 2017 Jan; 43(1):124-129. PubMed ID: 27743182
[TBL] [Abstract][Full Text] [Related]
17. Impact of gamma-glutamyl carboxylase gene polymorphisms on warfarin dose requirement: a systematic review and meta-analysis.
Sun Y; Wu Z; Li S; Qin X; Li T; Xie L; Deng Y; Chen J
Thromb Res; 2015 Apr; 135(4):739-47. PubMed ID: 25681132
[TBL] [Abstract][Full Text] [Related]
18. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.
Shahin MH; Khalifa SI; Gong Y; Hammad LN; Sallam MT; El Shafey M; Ali SS; Mohamed ME; Langaee T; Johnson JA
Pharmacogenet Genomics; 2011 Mar; 21(3):130-5. PubMed ID: 21228733
[TBL] [Abstract][Full Text] [Related]
19. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement.
Herman D; Peternel P; Stegnar M; Breskvar K; Dolzan V
Thromb Haemost; 2006 May; 95(5):782-7. PubMed ID: 16676068
[TBL] [Abstract][Full Text] [Related]
20. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
